DigestRedComo funciona
Red
/
Empresas
Je
No verificado

Jeito Capital

Sobre qué escribimos

Anuncios brevesFinanzasPublicidad/Marketing/Medios de comunicación/Comunicación

10 Comunicados de prensa

Ver todos los comunicados de prensa
15/10/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital promotes Ksenija Pavletic to General Partner
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
10/09/2025
Finanzas
Anuncios breves
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
20/05/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
12/05/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
11/05/2025
Finanzas
Anuncios breves
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
23/03/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
03/03/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
07/01/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital leads $67.5 million (€64.4 million[1]) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
07/01/2025
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0
12/11/2024
Finanzas
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors
Fuente
Jeito Capital
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0